Jessica Thomas
Hematology & Oncology · Royal Oak, MINPI 1235715715
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in MI, where the typical reported total is $1,604.
Across 44 payments — averaging $36.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$233
- Amgen$213
- Caris MPI, Inc.$205
- Merck$174
- Hologic Sales And Service, LLC$81
- Regeneron Healthcare Solutions, Inc.$72
- plus $615 from 17 others
What the payments were for
- Food & beverage$1,51895%
- Education$755%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 4 | $233 |
| Amgen | 2 | $213 |
| Caris MPI, Inc. | 2 | $205 |
| Merck | 7 | $174 |
| Hologic Sales And Service, LLC | 1 | $81 |
| Regeneron Healthcare Solutions, Inc. | 2 | $72 |
| Geron Corporation | 2 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Genentech USA, Inc. | 2 | $53 |
| Genmab U.S., Inc. | 2 | $51 |
| Johnson & Johnson | 2 | $50 |
| Lilly USA, LLC | 2 | $41 |
| Novartis | 2 | $41 |
| Sobi, Inc | 2 | $40 |
| Recordati_rare_diseases_inc. | 1 | $36 |
| Adaptive Biotechnologies Corporation | 1 | $36 |
| ADC Therapeutics America, Inc. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Array Biopharma Inc | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Deciphera Pharmaceuticals Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MI CANCER SEEK$168
- Blincyto$114
How this compares
$1,593 in reported general payments places this provider in the 45th percentile of 282 hematology & oncology providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 11 | $12,799 |
| Atorvastatin Calcium | 25 | $298 |
| Amlodipine Besylate | 31 | $157 |
| Lisinopril | 23 | $137 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Royal Oak
- Samer BallouzRoyal Oak$29K
- Matthew CotantRoyal Oak$17K
- Elisa QuirozRoyal Oak$13K
- Laura NadeauRoyal Oak$11K
- Martin TapiaRoyal Oak$10K
- Deepa JagtapRoyal Oak$9K
- Ishmael JaiyesimiRoyal Oak$9K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.